Regencell Bioscience Holdings Limited · NASDAQ:RGC
Regencell Bioscience — IPO Roadshow (July 2021)
22 slides from Regencell Bioscience's IPO roadshow presentation, Jul 8, 2021
Slide 1: Corporate Presentation July 2021
Regencell Bioscience Holdings Limited To improve the lives of ADHD and ASD patients, their families and caregivers & become a market leader for the best treatment of ADHD and ASD Corporate Presentation July 2021 Issuer Free Writing Prospectus dated July 8, 2021 Filed Pursuant to Rule 433 of the Secu
Slide 2: Free Writing Prospectus Statement
Regencell Bioscience Limited | 2 Free Writing Prospectus Statement ▪ This free writing prospectus relates to the proposed initial public offering of ordinary shares of Regencell Bioscience Holdings Limited (the “Company”), which are being registered on a registration statement and should be read tog
Slide 3: Forward Looking Statements
Regencell Bioscience Limited | 3 Forward Looking Statements All statements in this presentation, other than those relating to historical facts, are "forward - looking statements . ” These forward - looking statements may include, but are not limited to, statements relating to our objectives, plans,
Slide 4: Offering Summary
Regencell Bioscience Limited | 4 ISSUER: Regencell Bioscience Holdings Limited PROPOSED EXCHANGE // SYMBOL: Nasdaq Capital Market // RGC OFFERING TYPE : Initial Public Offering OFFERING SIZE: Approximately $ 21.9 million (excluding 15% over - allotment option) SECURITIES OFFERED: Ordinary shares PRI
Slide 5: About Us
Regencell Bioscience Limited | 5 About Us • We are an early - stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, with initial products in development for the trea
Slide 6: Investment Highlights
Regencell Bioscience Limited | 6 Investment Highlights • Addressing large neurocognitive disorders markets with unmet needs (combined global ADHD and ASD market size of $ 24 . 9 billion in 2019 ) • Lead products are proprietary TCM formulae based on over 30 years of Mr . Sik - Kee Au's clinical expe
Slide 7: Large Markets with Unmet Needs
Regencell Bioscience Limited | 7 Large Markets with Unmet Needs Main Symptoms ADHD Lack of attention, hyperactive, impulsive behavior, excessive physical movement and little or no sense of danger . Some may also have signs of anxiety, oppositional defiant and conduct disorder, depression and sleep p
Slide 8: ADHD Common Medications
Regencell Bioscience Limited | 8 ADHD Common Medications • Stimulants : H elp focus thoughts and ignore distractions . Work for 70 % to 80 % of people . Used to treat moderate and severe ADHD ( 1 ) • Non - stimulants : In cases where stimulants don’t work or cause unpleasant side effects, non - stim
Slide 9: Global ADHD and ASD market size forecast to grow
Regencell Bioscience Limited | 9 The global ADHD and ASD market size is forecasted to grow at a CAGR of 4 . 9 % and 5 . 9 % respectively from 2020 to 2030 , and 7 . 8 % and 4 . 9 % respectively in Hong Kong from 2019 to 2030 ADHD • The global ADHD drug market size was valued at $ 21 . 5 billion in 2
Slide 10: Our Proprietary TCM Formulae
Regencell Bioscience Limited | 10 Our Proprietary TCM Formulae • Sik - Kee Au TCM Brain Theory Я explains why a healthy brain is essential in restoring the body’s systems to normal from disorders and illnesses such as ADHD and ASD • According to the Sik - Kee Au TCM Brain Theory Я , the blockage or
Slide 11: Our TCM Formulae Candidates
Regencell Bioscience Limited | 11 Our TCM Formulae Candidates • One theory : all formulae are developed based on Sik - Kee Au TCM Brain Theory Я • Two components in each TCM formula candidate : standard base formula + fixed adjusted formula • Three liquid - based TCM formulae candidates (mild, moder
Slide 12: Our First Research Study
Regencell Bioscience Limited | 12 Our First Research Study • C ommenced in November 2018 ( 6 patients) and March 2019 ( 1 patient) • Seven patients, from five to twelve years old, who were clinically diagnosed with ADHD or ASD by healthcare professionals • Each enrolled patient stopped all existing
Slide 13: Our First Research Study Results
Regencell Bioscience Limited | 13 Our First Research Study Results Notes: 1. Lower Scores Indicate Lower Severity 2. Patients were treated by the TCM Practitioner with the use of personalized TCM formulae 3. Six patients were treated for three months and one patient (Patient 7) was treated for only
Slide 14: Our First Research Study Results (Cont'd)
Regencell Bioscience Limited | 14 Our First Research Study Results (Cont’d) Regencell Bioscience Holdings Limited VADRS Total (Score Range: 0 - 141) Patient Scores Before Treatment Scores After 3 Months of Treatment Percentage Change in Scores Patient 1 60 37 -38 % Patient 2 66 61 -8 % Patient 3 57
Slide 15: Our Planned Second Research Study
Regencell Bioscience Limited | 15 Our Planned Second Research Study Objective • Verify the effectiveness of the standardized TCM formulae candidates for mild, moderate and severe conditions • Provide foundation for proprietary Chinese medicine (“pCm”) registration Study Design • Sample size: 100 pat
Slide 16: Approximately four years to commercialize in Hong Kong
Regencell Bioscience Limited | 16 We estimate that it will take us approximately four years to commercialize our standardized TCM formulae candidates in Hong Kong : • Approximately one year to complete our second research study, including enrollment of qualified patients for treatment by qualified T
Slide 17: Development Strategy and Timeline
Regencell Bioscience Limited | 17 Development Strategy and Timeline Note: The projected timeline above is what we aim to achieve but there is no guarantee that any of the listed milestones will be met in the time noted or at all. Regencell Bioscience Holdings Limited See offering documents for furth
Slide 18: Management Team
Regencell Bioscience Limited | 18 ▪ Established Regencell in 2014 ▪ Founding partner of one of California’s largest group of property investors which partners with the leading pension and private equity funds with assets over US $ 250 billion ▪ Bachelor of Science degree from the Haas School of Busi
Slide 19: Independent Directors
Regencell Bioscience Limited | 19 Independent Directors ▪ Over 20 years of retail and brand management experience ▪ 18 - year at the Dairy Farm Company Limited, a leading pan - Asian retailer, responsible for product development, brand building, customer loyalty, and sales and profitability of multi
Slide 20: Use of Proceeds
Regencell Bioscience Limited | 20 Use of Proceeds • We plan to use the estimated IPO net proceeds of $19.3M (if no over - allotment is exercised) for the following purposes, with an estimated total of $29M needed to attain approval of our pCm formulae in Hong Kong: Note: (1) Estimated The foregoing
Slide 21: Commitments from strategic partner and Chairman
Regencell Bioscience Limited | 21 ▪ Commitments from our strategic partner, Mr . Sik - Kee Au • Dedicated to treat people afflicted with incurable illnesses, disorders and degeneration • Inventor of the TCM formulae that form the basis for our TCM formulae products for ADHD and ASD • Contributed all
Slide 22: Thank You
Thank You
Regencell Bioscience Holdings — IPO Roadshow (July 2021) on 6ix